exenatide

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Jan 1, 2010 → Sep 1, 2011

NCT ID

NCT01056549

About exenatide

exenatide is a pre-clinical stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01056549. Target conditions include Hyperlipidemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01373216	Phase 3	Completed	Jun 1, 2011	Dec 1, 2014	Coronary Artery Disease
NCT01056549	Pre-clinical	Completed	Jan 1, 2010	Sep 1, 2011	Hyperlipidemia
NCT00753896	Phase 3	Completed	Oct 1, 2008	Nov 1, 2009	Type 2 Diabetes
NCT00529204	Phase 2	Terminated	Oct 1, 2007	Feb 1, 2010	Diabetes Complications
NCT00516048	Phase 3	Completed	Aug 1, 2007	Apr 1, 2008	Type 2 Diabetes Mellitus
NCT01876849	Phase 3	Completed	Dec 1, 2003	Jul 1, 2008	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Hyperlipidemia

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebo	Viking Therapeutics	Phase 2	47
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo	Yuhan	Phase 3	77
Diet+pravastatin	Daiichi Sankyo	Approved	85
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	85
Minute Maid Heart Wise orange juice + Welchol	Daiichi Sankyo	Approved	85
Pravafen + Pravastatin + Fenofibrate	Shionogi	Phase 3	77
Evacetrapib + Atorvastatin + Ezetimibe + Placebo	Eli Lilly	Phase 3	77
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC	Eli Lilly	Phase 1	33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	41
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 2	52
Rosuvastatin (Crestor)	AstraZeneca	Approved	85
simvastatin + Ezetimibe	Merck	Approved	85
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	77
simvastatin 20 mg/ezetimibe	Merck	Phase 2/3	65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin	Merck	Phase 3	77
Sitagliptin + Placebo	Merck	Phase 2/3	65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)	Novartis	Phase 1	33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved